Latest News - Pfizer
Top Corporates Hub
Pfizer
Novo Nordisk cuts 9,000 jobs as it looks to new weight-loss drugs
31.10.2025 12:52
STORY: :: Novo Nordisk Novo Nordisk has almost completed notifying employees impacted by the drugmaker's 9,000 job cuts.That’s according to a LinkedIn post by CEO Mike Doustdar Friday. As jobs were slashed globally, he added that the pace of informing people varied according to local laws. It’s part of Doustdar’s restructuring drive which he launched last month. And comes as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly.The $150 billion weight-loss drug market is booming and Novo’s setting its sights on newer heights. :: Pfizer The Danish pharma giant and another major rival Pfizer are in a bidding war over obesity biotech Metsera’s hottest experimental treatments. The drugmakers are vying for access to its once-monthly GLP-1 injectable.Current popular injectables, including Novo’s Wegovy and Eli Lilly’s Zepbound, are weekly shots. Metsera is one of several companies developing experimental weight-loss drugs.The move signals an aggressive turn by Novo Nordisk a week after the ousting of most of the company's board.That was over concerns it was not moving fast enough in the obesity market.
Pfizer Faces Off With Novo Nordisk Over Metsera Bid
31.10.2025 12:25
U.S. drugmaker may leverage political ties as takeover battle intensifies
Jim Cramer on Pfizer: “The Drug Stocks Are Just in a World of Hurt, and This One Continues to Be There”
31.10.2025 02:30
Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently talked about. During the lightning round, when a caller asked about the stock, Cramer commented: “I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to change it. But […]
Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages
30.10.2025 13:56
Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of Singapore approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA). The approval makes Singapore the first country in Southeast Asia to fully […]
Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings.
30.10.2025 13:49
Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs.
Novo Nodrisk stock dips on aggressive odder to buy Metsera, ’reckless’ says Pfizer
30.10.2025 13:13
Investing.com -- Novo Nordisk shares have slipped over 2% premarket on Thursday after the company made an unsolicited bid to acquire Metsera, a U.S. obesity drug developer, in a move BMO Capital described as “an over-the-top bid” that complicates Pfizer’s ongoing takeover attempt.
Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle
30.10.2025 12:54
Novo offered to buy Metsera Inc. for at least $6.5 billion, seeking to trump an earlier agreed deal with Pfizer. Metsera called the new offer, which Bloomberg News reported earlier on Thursday, superior to the previous one from Pfizer that it had accepted last month.
Metsera Becomes The Prize In Obesity's Biggest Bidding War
30.10.2025 12:54
Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about MTSR stock here.
Update: Pfizer Calls Novo Nordisk's Metsera Acquisition Proposal 'Reckless'
30.10.2025 12:48
(Update with details throughout and Novo Nordisk's reply to a request for comment.) Pfizer (PFE)
Metsera Receives Unsolicited Proposal from Novo Nordisk
30.10.2025 11:07
Metsera, Inc. (NASDAQ: MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) ("Novo Nordisk") to acquire Metsera (the "Novo Nordisk Proposal") constitutes a "Superior Company Proposal" as defined in Metsera's existing Merger Agreement with Pfizer (the "Pfizer Merger Agreement").
Pfizer Addresses Proposal for Metsera
30.10.2025 10:57
NEW YORK, October 30, 2025--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk. The proposal is illusory and cannot qualify as a sup
Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera
30.10.2025 10:56
The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed obesity-drug developer.
Pfizer and Roche place $10bn bets on obesity and liver disease therapies as Trump tightens grip on drug pricing and manufacturing
30.10.2025 10:32
The deals come against a backdrop of sweeping trade and pricing policies from Trump’s administration.
Crinetics Pharmaceuticals: Its Post-FDA Approval Future
30.10.2025 10:24
Crinetics Pharmaceuticals (CRNX) stock has surged after FDA approval of Palsonify for acromegaly. Read the latest analysis on the stock here.
Novo tops Pfizer with $6.5B bid for Metsera
30.10.2025 07:54
Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would "maximize the potential of Metsera's complementary portfolio and capabilities."
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
27.10.2025 16:45
Saint-Herblain (France), October 27, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the upcoming Phase 3 trial outcomes for VLA15, the Company
Should You Buy Pfizer Stock Before Nov. 4?
27.10.2025 16:15
The pharma giant is slated to report its latest quarterly numbers next week.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
27.10.2025 13:17
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
2 Unstoppable Health Care Giants to Buy Right Now for Less Than $1,000
27.10.2025 12:00
These two healthcare giants are doing what they need to do to get their businesses rocking and rolling again.
Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030
27.10.2025 09:43
Vertex appears to be by far the better buy right now.